Over 2 years have passed since the start of the COVID-19 pandemic, which has claimed
millions of lives. Unlike the early days of the pandemic, when management decisions were …

Mpox virus is an emergent human pathogen. While it is less lethal than smallpox, it can still
cause significant morbidity and mortality. In this review, we explore 3 antiviral agents with …

Up to 87% of patients hospitalized with coronavirus disease 2019 (COVID-19) experience
chronic sequelae following infection. The long-term impact of COVID-19 infection on kidney …

Acute kidney injury (AKI) is a common complication among patients with the novel
coronavirus (COVID-19). COVID-19 along with AKI usually resulted in a poor prognosis for …

An enveloped double-stranded DNA monkeypox virus (MPXV) is a causative agent of the
zoonotic viral disease, human monkeypox (HMPX). MPXV belongs to the genus …

Introduction The approach to evaluating nephrotoxins in studies of drug-associated acute
kidney injury varies. Some studies use a list of under ten drugs for evaluation whereas …

Background Remdesivir is approved by the US Food and Drug Administration for the
treatment of patients hospitalized with coronavirus disease 2019 (COVID-19) and has been …

Background: Remdesivir has been used for treating patients with moderate to severe
coronavirus disease 2019 (COVID-19) although there is conflicting evidence regarding its …

Background Remdesivir is not currently approved for patients with eGFR< 30 ml/min per
1.73 m 2. We aimed to determine the safety of remdesivir in patients with kidney failure …

The objective of this study was to describe the population pharmacokinetics of remdesivir
and GS-441524 in hospitalized coronavirus disease 2019 (COVID-19) patients. A …